Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

The midcap biotech just became an even better buy.There is a loose relationship between price and quality on the stock market. Penny stocks are overwhelmingly regarded as high risk, while many larger-cap shares trade at high prices.Still, it's possible to find solid businesses whose share prices aren't too high -- perhaps following a recent stock split or because the market is ignoring their potential, or for some other reason. In other words, there is no need to break the bank to invest in quality companie ...

Exelixis (EXEL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 29 ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE . I have embraced employing covered call holdings around most of my small and midcap biotech positions over the past five to six years. Option premiums around this high-beta part of ...

I'm a biotech and healthcare investment analyst with several years of clinical experience and a Master of Business Administration. I've had the privilege of sharing my analyses on Seeking Alpha since 2017. Outside of spending time with family, this is my favorite thing to do. I utilize risk-return charts and DCF analyses to highlight investment opportunities and risks. I'm a big fan of the barbell strategy: 90% in safe assets like Treasuries and ETFs, and 10% in high-growth stocks—keeping risk management fr ...

Exelixis (EXEL) shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks. Exelixis' shares gained on a favorable court ruling against MSN Laboratories for a generic product of lead drug Cabometyx (related to cabozantinib). The Delaware District Court ruled in Exelixis' favor, rejecting MSN's challenge to three listed patents rela ...

Exelixis, Inc. (EXEL) announced that the District Court of Delaware has ruled in its favor in the second patent litigation against MSN Laboratories. MSN is seeking approval for its generic product of Exelixis' cabozantinib. Details of EXEL's Patent Litigation Cabozantinib is marketed under the brand name Cabometyx for the treatment of renal cell carcinoma (RCC). EXEL has been involved in a lawsuit with MSN since 2019, when the latter submitted an abbreviated new drug application (ANDA) to the FDA requesting ...

Exelixis, Inc. (EXEL) entered into a clinical development collaboration agreement with pharma giant Merck (MRK) to advance the development of its pipeline candidate, zanzalintinib. Zanzalintinib, an investigational tyrosine kinase inhibitor (TKI), inhibits multiple cancer-related pathways that play a key role in resistance to multiple therapies, including immune checkpoint inhibitors. Shares of Exelixis have risen 9.4% year to date compared with the industry's growth of 6.3%. Image Source: Zacks Investment ...

Shares of Exelixis, Inc. (EXEL) have risen 20.7% in the past three months compared with the industry's growth of 6.3%. The stock has also outperformed the sector and the S&P 500 Index. Exelixis has been a consistent outperformer in the year so far on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress. EXEL Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Cabometyx Boosts EXEL Cabometyx maintained its status as the leading tyrosine ki ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revisi ...